- Global license and collaboration agreement to focus on the
development of OSE-230, a monoclonal antibody designed to resolve
chronic inflammation
- OSE Immunotherapeutics to receive an upfront payment of $48
million and will be eligible to receive up to an additional $665
million in milestone payments
Regulatory News:
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240227944027/en/
AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN:
FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company,
today announced a strategic partnership to develop OSE-230, a
monoclonal antibody designed to resolve chronic and severe
inflammation, currently in the pre-clinical development stage.
OSE-230 is a first-in-class monoclonal antibody designed to
activate ChemR23, a GPCR (G-Protein Coupled Receptor) target.
Activation of ChemR23 may offer a novel mechanism for resolution of
chronic inflammation, modulating functions of both macrophages and
neutrophils.
“This collaboration underscores our commitment to expanding our
immunology portfolio with the ultimate goal of improving the
standard of care for patients living with inflammatory diseases
globally,” said Jonathon Sedgwick, Ph.D., senior vice president and
global head of discovery research, AbbVie. “By leveraging our
expertise in immunology drug development, we look forward to
advancing OSE-230, which offers a novel mechanism-of-action to
treat chronic inflammation.”
“We are very pleased to collaborate with AbbVie, a global leader
in the development and commercialization of innovative medicines,
to drive our OSE-230 program forward,” said Nicolas Poirier, chief
executive officer, OSE Immunotherapeutics. “This partnership
represents a major milestone in our company’s progress and
recognizes the value of our innovative R&D capabilities. I
would like to thank all our employees who helped us reach this
milestone through dedication and hard work.”
Under the terms of the agreement, AbbVie will receive an
exclusive global license to develop, manufacture and commercialize
OSE-230. OSE Immunotherapeutics will receive a $48 million upfront
payment and will be eligible to receive up to an additional $665
million in clinical development, regulatory and commercial
milestones. In addition, OSE Immunotherapeutics will be eligible to
receive potential tiered royalties on global net sales of
OSE-230.
The transaction is subject to the satisfaction of customary
closing conditions, including the applicable waiting period under
the Hart-Scott-Rodino Antitrust Improvements Act.
About AbbVie AbbVie's mission is to discover and deliver
innovative medicines and solutions that solve serious health issues
today and address the medical challenges of tomorrow. We strive to
have a remarkable impact on people's lives across several key
therapeutic areas – immunology, oncology, neuroscience, and eye
care – and products and services in our Allergan Aesthetics
portfolio. For more information about AbbVie, please visit us at
www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X
(formerly Twitter), and YouTube.
ABOUT OSE Immunotherapeutics OSE Immunotherapeutics is a
biotech company dedicated to developing first-in-class assets in
immuno-oncology (IO) and immuno-inflammation (I&I). The
Company’s current well-balanced first-in-class clinical pipeline
includes:
- Tedopi® (immunotherapy activating tumor specific
T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is
the Company’s most advanced product; positive results from the
Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients
in secondary resistance after checkpoint inhibitor failure. Other
Phase 2 trials, sponsored by clinical oncology groups, of Tedopi®
in combination are ongoing in solid tumors.
- OSE-279 (anti-PD1): first positive results in the
ongoing Phase 1/2 in solid tumors. OSE-279 is the backbone therapy
of the BiCKI® platform.
- OSE-127 - lusvertikimab (humanized monoclonal antibody
antagonist of IL-7 receptor); ongoing Phase 2 in Ulcerative Colitis
(sponsor OSE Immunotherapeutics); ongoing preclinical research in
leukemia (OSE Immunotherapeutics).
- FR-104/VEL-101 (anti-CD28 monoclonal antibody):
developed in partnership with Veloxis Pharmaceuticals, Inc. in
transplantation; ongoing Phase 1/2 in renal transplant (sponsor
Nantes University Hospital); Phase 1 ongoing in the US (sponsor
Veloxis Pharmaceuticals, Inc.).
- BI 765063 and BI 770371 (anti-SIRPα monoclonal
antibody on CD47/SIRPα pathway) developed in partnership with
Boehringer Ingelheim in advanced solid tumors; positive Phase 1
dose escalation results in monotherapy and in combination, in
particular with anti-PD-1 antibody ezabenlimab; international Phase
1b ongoing clinical trial in combination with ezabenlimab alone or
with other drugs in patients with recurrent/metastatic head and
neck squamous cell carcinoma (HNSCC) and hepatocellular carcinoma
(HCC).
- OSE-230 (ChemR23 agonist mAb) developed in partnership
with AbbVie in chronic inflammation.
OSE Immunotherapeutics expects to generate further significant
value from its three proprietary drug discovery platforms, which
are central to its ambitious goal to deliver next-generation
first-in-class immunotherapies:
- Pro-resolutive mAb platform focused on targeting and
advancing inflammation resolution and optimizing the therapeutic
potential of targeting Neutrophils and Macrophages in I&I.
OSE-230 (licensed to AbbVie) is the first candidate
generated by the platform, additional discovery programs ongoing on
new pro-resolutive GPCRs.
- Myeloid Checkpoint platform focused on optimizing the
therapeutic potential of myeloid cells in IO by targeting immune
regulatory receptors expressed by Macrophages and Dendritic cells.
BI 765063 and BI 770371 (licensed to Boehringer
Ingelheim) are the most advanced candidates generated by the
platform. Ongoing additional discovery programs, in particular with
positive preclinical results obtained in monotherapy with new
anti-CLEC-1 mAbs.
- Cytokine platform focused on leveraging the Cis-Delivery
of cytokine in IO and I&I. BiCKI® is a bispecific fusion
protein platform built on the key backbone component of anti-PD1
combined with a new immunotherapy target to increase anti-tumor
efficacy. BiCKI®-IL-7v is the most advanced BiCKI®
candidate targeting anti-PD1xIL-7. Ongoing additional discovery
programs on Cis-Demasking technologies.
AbbVie Forward-Looking Statements Some statements in this
news release are, or may be considered, forward-looking statements
for purposes of the Private Securities Litigation Reform Act of
1995. The words "believe," "expect," "anticipate," "project" and
similar expressions and uses of future or conditional verbs,
generally identify forward-looking statements. AbbVie cautions that
these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially
from those expressed or implied in the forward-looking statements.
Such risks and uncertainties include, but are not limited to,
challenges to intellectual property, competition from other
products, difficulties inherent in the research and development
process, adverse litigation or government action, and changes to
laws and regulations applicable to our industry. Additional
information about the economic, competitive, governmental,
technological and other factors that may affect AbbVie's operations
is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual
Report on Form 10-K, which has been filed with the Securities and
Exchange Commission, as updated by its subsequent Quarterly Reports
on Form 10-Q. AbbVie undertakes no obligation, and specifically
declines, to release publicly any revisions to forward-looking
statements as a result of subsequent events or developments, except
as required by law.
OSE Forward-looking statements This press release
contains express or implied information and statements that might
be deemed forward-looking information and statements in respect of
OSE Immunotherapeutics. They do not constitute historical facts.
These information and statements include financial projections that
are based upon certain assumptions and assessments made by OSE
Immunotherapeutics’ management in light of its experience and its
perception of historical trends, current economic and industry
conditions, expected future developments and other factors they
believe to be appropriate.
These forward-looking statements include statements typically
using conditional and containing verbs such as “expect”,
“anticipate”, “believe”, “target”, “plan”, or “estimate”, their
declensions and conjugations and words of similar import. Although
the OSE Immunotherapeutics management believes that the
forward-looking statements and information are reasonable, the OSE
Immunotherapeutics’ shareholders and other investors are cautioned
that the completion of such expectations is by nature subject to
various risks, known or not, and uncertainties which are difficult
to predict and generally beyond the control of OSE
Immunotherapeutics. These risks could cause actual results and
developments to differ materially from those expressed in or
implied or projected by the forward-looking statements. These risks
include those discussed or identified in the public filings made by
OSE Immunotherapeutics with the AMF. Such forward-looking
statements are not guarantees of future performance. This press
release includes only summary information and should be read with
the OSE Immunotherapeutics Universal Registration Document filed
with the AMF on May 2, 2023, including the annual financial report
for the fiscal year 2022, available on the OSE Immunotherapeutics’
website. Other than as required by applicable law, OSE
Immunotherapeutics issues this press release at the date hereof and
does not undertake any obligation to update or revise the
forward-looking information or statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240227944027/en/
AbbVie : Media Sourojit (Jit) Bhowmick, Ph.D.
Jit.bhowmick@abbvie.com
Investors Liz Shea liz.shea@abbvie.com
OSE Immunotherapeutics : Nicolas Poirier Chief Executive
Officer nicolas.poirier@ose-immuno.com
Sylvie Détry Corporate communication-Secretary general
sylvie.detry@ose-immuno.com
French Media FP2COM Florence Portejoie
fportejoie@fp2com.fr +33 6 07 768 283
U.S. Media RooneyPartners LLC Kate Barrette
kbarrette@rooneypartners.com +1 212 223 0561
OSE Immunotherapeutics (EU:OSE)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
OSE Immunotherapeutics (EU:OSE)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
